ArticleJournal of clinical medicine2022
The Utility of Pre-Treatment Inflammation Markers as Associative Factors to the Adverse Outcomes of Vulvar Cancer: A Study on Staging, Nodal Involvement, and Metastasis Models.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 6 citations in OpenAlex.
- Article
- Prognostic Value of the Nutritional Risk Index and Hemoglobin-to-Platelet Ratio Score for Predicting Recurrence and Survival in Siewert II/III Gastroesophageal Junction Adenocarcinoma.Journal of gastrointestinal cancer · 2026Article
- Temporal Trends in Vulvar Cancer Cases and Associated Factors of Adverse Clinical Features: A 6-year Retrospective Study From a Tertiary Hospital in Indonesia.International journal of women's health · 2026Article
- The Accuracy and Sensitivity of Delta Neutrophil Index in Malignancy: Diagnostic Study of Different Types.Diagnostics (Basel, Switzerland) · 2025Article
- Inflammation as a mediator between neck adipose tissue and tumor aggressiveness in hypopharyngeal and laryngeal squamous cell carcinoma.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Role of hematological biomarkers in predicting oncological outcomes of definitive chemoradiation in locally advanced vulvar carcinoma.Journal of biological methods · 2025Article
- Article
- Expression of Inflammation Depending on the Stage of Cervical Cancer.Medicina (Kaunas, Lithuania) · 2024Article
- Factors associated with vulvar cancer from 2005 to 2021 in Togo, sub-Saharan Africa.BMC women's health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiven the role of inflammation in carcinogenesis, this study investigated the utility of pre-treatment inflammatory markers as associative indicators for advanced-stage disease, lymph node metastasis (LNM), and distant metastasis (DM) in vulvar cancer (VC).
methodsA cross-sectional study was conducted on 86 women with VC in a single centre in Jakarta, Indonesia. The laboratory data was based on C-reactive protein (CRP), procalcitonin, the erythrocyte sedimentation rate (ESR) and fourteen derived, recorded and calculated ratios: leukocyte-to-platelet (LPR), neutrophil-to-lymphocyte (NLR), derived neutrophil-to-lymphocyte (dNLR), neutrophil-to-monocyte (NMR), platelet-to-monocyte (PLR), lymphocyte-to-monocyte (LMR), basophil-to-monocyte (BLR), systemic immune-inflammation index (SII), body mass index, albumin, and NLR (BAN) score, haemoglobin-to-platelet (HPR), prognostic nutritional index (PNI), modified Glasgow Prognostic Score (mGPS), CRP-to-albumin, and CRP-to-procalcitonin. The optimal cut-off for each marker was determined using receiver operating characteristic (ROC) curve analysis, and their diagnostic indicator performances were assessed. The utility of these ratios as associative factors for three endpoints was further evaluated in multivariate regression models.
resultsInvestigated inflammatory markers exhibited specific performances for individual adverse outcomes, proving a fair to excellent ability in case finding and screening. After adjustment, the BAN score ≤ 334.89 (OR 9.20,
conclusionsInflammatory markers are crucial for identifying the deleterious outcomes of VC. Accordingly, yielded models require external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.